eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
8/2003
vol. 7
 
Share:
Share:
abstract:

Melanoma vaccines

Andrzej Mackiewicz
,
Piotr J. Wysocki

Współcz Onkol (2003) vol. 7, 8 (626-629)
Online publish date: 2003/11/05
View full text Get citation
 
Malignant melanoma is an immunogenic tumor, and its spontaneous remissions are associated with activation of the immune system. Discovery of this fact induced a rapid progress in the field of immunology of this cancer and in the development of novel strategies of immunotherapy. Characterization of immune mechanisms responsible for recognition and rejection of cancer cells paved the way for construction of melanoma vaccines. Up to now, the efficacy of different types of melanoma vaccines (antigenic, cellular, DNA, GMTV, DC) has been analyzed in numerous clinical trials. However, results of these trials are still unsatisfactory. As yet there is no phase III clinical trials that demonstrated a statistically significant difference between vaccine and control groups in term of overall – (OS) and disease free survival (DFS). Signs of immune system activation that has been observed in patients receiving melanoma vaccines did not correlate with clinical outcomes.
In a clinical trial carried out in our department since 1995 we have been evaluating the efficacy of GMTV modified with a gene complex encoding IL-6 and sIL-6R. In the phase II trial the 60% response rate was achieved (CR – 15%, PR – 15%, SD – 25%). The DFS of patients immunized after surgical removal of metastases has been extended from 7 to 24 months. The OS cannot has not been determined yet, since the majority of patients is still alive (observation time ~4 years). In January 2004 we will begin recruitment of patients for the phase III clinical trial (randomized, double-blind, placebo controlled study). The study will be carried out in main polish oncology centers.
keywords:

melanoma vaccines, immunotherapy, clinical trial

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.